Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Allopurinol and Chronic Kidney Disease. Reply.
Doria A, Galecki AT, Mauer M; PERL Study Group. Doria A, et al. N Engl J Med. 2020 Oct 22;383(17):1690-1691. doi: 10.1056/NEJMc2026125. N Engl J Med. 2020. PMID: 33085876 No abstract available.
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M; PERL Study Group. Doria A, et al. N Engl J Med. 2020 Jun 25;382(26):2493-2503. doi: 10.1056/NEJMoa1916624. N Engl J Med. 2020. PMID: 32579810 Free PMC article. Clinical Trial.
Baseline risk markers and visit-to-visit variability in relation to kidney outcomes - A post-hoc analysis of the PERL study.
Rotbain Curovic V, Roy N, Hansen TW, Luiza Caramori M, Cherney DZ, De Boer IH, Emanuele MA, Hirsch IB, Lingvay I, Mcgill JB, Polsky S, Pop-Busui R, Sigal RJ, Tuttle KR, Umpierrez GE, Wallia A, Rosas SE, Rossing P; PERL Study Group. Rotbain Curovic V, et al. Diabetes Res Clin Pract. 2022 Nov;193:110119. doi: 10.1016/j.diabres.2022.110119. Epub 2022 Oct 17. Diabetes Res Clin Pract. 2022. PMID: 36265753 Clinical Trial.
Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.
Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, Doria A; PERL Study Group. Afkarian M, et al. Diabetes Care. 2019 Aug;42(8):1454-1463. doi: 10.2337/dc19-0342. Epub 2019 Jun 11. Diabetes Care. 2019. PMID: 31186299 Free PMC article. Clinical Trial.